NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE168017 Query DataSets for GSE168017
Status Public on Mar 03, 2021
Title Impaired antibacterial immune signaling and changes in the lung microbiome precedes secondary bacterial pneumonia in COVID-19 (bulkRNA-seq)
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary We preformed a systems biological assessment of lower respiratory tract host immune responses and microbiome dynamics in COVD-19 patients, using bulk RNA-sequencing, single-cell RNA sequencing, and techniques, and microbiome analysis. Are focus was on differential gene expression in severe COVID-19 patients who developed ventilator associated pneumonia (VAP) during their course versus severe COVID-19 patients who did not develop VAP. We found early impairment in antibacterial immune signaling in patients two or more weeks prior to the development of VAP, compared to COVID-19 patients who did not develop VAP. There was no signficant difference in viral load, but an association of disruption in lung microbiome by alpha and beta diversity metrics was also found.
 
Overall design Tracheal aspirate samples were processed for either bulk or single-cell RNA sequencing: 1) Bulk RNA-sequencing from 7 patients with severe COVID-19 patients who developed VAP, 10 COVID-19 patients who did not develop VAP, and 8 patients intubated but COVID-19 negative; 2) Single cell RNA-sequencing from 7 COVID-19 patients who developed VAP and 8 COVID-19 patients who did not develop VAP. Differential gene expression was analyzed for COVID-19 patients who developed VAP versus those who did not at: a) "early" time-point (median 2 days post intubation), 2) "late" time-point (median 2 days before VAP diagnosis), and when available c) differential gene expression also analyzed in those who developed VAP comparing the "early" and "late" time-points. Lastly, differential gene expression was done in the bulk RNA-sequencing in COVID-19 positive versus control patients at the "early" time-point.
*** Raw data is not included in this GEO submission due to patient privacy concerns ***
 
Contributor(s) Tsitsiklis A, Zha BS, Byrne A, DeVoe C, Sunshine S
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Mar 02, 2021
Last update date Jul 12, 2024
Contact name Beth Shoshana Zha
E-mail(s) shoshana.zha@ucsf.edu
Organization name University of California San Francisco
Department Medicine
Street address 400 Parnassus Ave
City San Francisco
State/province CA
ZIP/Postal code 94143
Country USA
 
Platforms (1)
GPL27644 Illumina Novaseq 6000 (Homo sapiens)
Samples (102)
GSM5123823 1001: RR100e_00001
GSM5123824 1001: RR100e_00002
GSM5123825 1001: RR100e_00003
This SubSeries is part of SuperSeries:
GSE168019 Impaired antibacterial immune signaling and changes in the lung microbiome precedes secondary bacterial pneumonia in COVID-19
Relations
BioProject PRJNA705883

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE168017_genecounts_all_bulk.csv.gz 2.3 Mb (ftp)(http) CSV
GSE168017_metadata_all_bulk.csv.gz 1013 b (ftp)(http) CSV
Processed data are available on Series record
Raw data not provided for this record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap